Business Context and Reporting Period
This Form 8-K filing by vTv Therapeutics Inc. (VTVT) covers events occurring on September 26 and September 27, 2019. The company, an emerging growth company incorporated in Delaware, reported the entry into a material definitive agreement with MacAndrews & Forbes Group LLC (the "Investor") to secure future funding.
Key Financial Metrics and Transaction Details
- Agreement Capacity: The Investor committed to purchase up to $10.0 million of Class A common stock at the Company's option over a one-year period.
- Share Price: The purchase price is fixed at $1.46 per share, matching the closing price on September 25, 2019.
- Warrants Issued: The Investor received warrants to purchase 400,990 shares at an exercise price of $1.68 per share (115% of the option price), exercisable until September 26, 2026.
- Initial Funding: On September 27, 2019, the Company exercised its option to sell 1,369,863 shares, raising $2,000,000 in cash.
- Investor Ownership: As of September 26, 2019, the Investor and its affiliates held approximately 81.5% of the Company's combined voting power.
Material Changes
The primary material change is the establishment of a committed capital facility with a major shareholder. This agreement provides the Company with a mechanism to raise up to $10.0 million on demand, subject to the execution of definitive documentation for each drawdown. The filing also notes the immediate execution of the first drawdown, resulting in a $2.0 million cash inflow and the issuance of new shares.
Outlook, Risks, and Contingencies
- Related Party Transaction: The agreement involves a related party, as the Investor holds a controlling interest (81.5%) and one of the Company's directors is an employee of the Investor. The transaction was approved under the Company's Related Person Transactions Policy.
- Contingency: The obligation to fund and issue shares is contingent upon the execution of mutually acceptable definitive documentation at the time of any funding request.
- Regulatory Status: The securities issued under this agreement are unregistered, relying on an exemption under Regulation D of the Securities Act of 1933.
- Financial Metrics: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or total debt levels outside of the specific transaction details.
Investor Verification Checklist
- Verify the execution of definitive documentation for the initial $2.0 million drawdown and subsequent potential drawdowns.
- Confirm the dilution impact of the 1,369,863 shares issued and the potential issuance of up to 6.85 million additional shares under the $10.0 million facility.
- Review the full text of the September 2019 Letter Agreement and Warrants, which are filed as exhibits to the Form 10-Q for the quarter ending September 30, 2019.
- Assess the liquidity position of the Company post-transaction, noting that the filing does not disclose total cash balances or burn rate.